Related Experiment Video
Updated: Apr 23, 2026

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
Published on: August 2, 2016
Cascade-Responsive Zwitterionic Polyprodrugs Leverage Fast Transcytosis for Deep Tumor Penetration and Intracellular
Yufei Cao1, Moujiang Zheng1, Davron Turgunov2
1School of Chemistry, State Key Laboratory of Fluorine & Nitrogen Chemicals, Institute of New Concept Sensors and Molecular Materials (INCSMM), Engineering Research Center of Energy Storage Materials and Devices, Ministry of Education, Xi'an Key Laboratory of Sustainable Polymer Materials, Xi'an Jiaotong University, Xi'an 710049, P.R. China.
Abstract:
The clinical translation of anticancer nanomedicines is significantly hindered by their inability to efficiently navigate the entire physiological CAPIR barriers (Circulation, Accumulation, Penetration, Internalization, and Release). To address this issue, we construct intelligent zwitterionic polyprodrugs, P(OC7A-DOX), which self-assemble into micelles. The design integrates cascade tumor-specific responses: (1) a hydrophilic shell of hypoxia-responsive poly(2-(N-oxide-hexamethyleneimino) ethyl methacrylate) (POC7A) that undergoes charge reversal in the tumor hypoxic and acidic microenvironment, and (2) a hydrophobic core containing doxorubicin (DOX) conjugated via a glutathione (GSH)-cleavable disulfide bond. Our study reveals that this system successfully orchestrates a spatial-temporal performance shift across the CAPIR cascade requirements. Importantly, the micelles maintain prolonged circulation due to the stealthy POC7A corona. Upon accumulation in hypoxic and acidic tumors, the POC7A segments are reduced and protonated, switching the surface property to a positively charged one, which dramatically enhances tumor tissue penetration and facilitates rapid cellular internalization via a transcytosis-like mechanism. Subsequently, the high intracellular GSH concentration triggers release of free DOX. In 4T1 tumor-bearing mice, they achieve significant tumor growth suppression with markedly reduced systemic toxicity compared to free DOX. This work provides an integrated nanoplatform that overcomes the key physiological barriers efficiently as a clinically promising nanomedicine.
Insights
Intelligent nanomedicines overcome physiological barriers for enhanced cancer treatment. These zwitterionic polyprodrugs improve circulation, tumor penetration, and drug release, reducing systemic toxicity.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Drug Delivery
Background:
- Clinical translation of nanomedicines is limited by physiological barriers (Circulation, Accumulation, Penetration, Internalization, Release).
- Overcoming these barriers requires advanced nanocarrier designs for efficient drug delivery.
Purpose of the Study:
- To develop intelligent zwitterionic polyprodrug micelles (P(OC7A-DOX)) that address the CAPIR barriers.
- To engineer a nanoplatform with cascade tumor-specific responses for improved anticancer efficacy.
Main Methods:
- Self-assembly of zwitterionic polyprodrugs into micelles with a hypoxia-responsive shell (POC7A) and a drug-loaded core (DOX).
- Utilizing a glutathione (GSH)-cleavable disulfide bond for drug conjugation.
- Evaluating the nanoplatform's performance in vitro and in vivo using 4T1 tumor-bearing mice.
Main Results:
- The P(OC7A-DOX) micelles demonstrated prolonged circulation and enhanced tumor accumulation.
- Charge reversal in the tumor microenvironment improved penetration and cellular internalization.
- High intracellular GSH levels triggered efficient doxorubicin release, leading to significant tumor growth suppression.
- Reduced systemic toxicity compared to free doxorubicin was observed.
Conclusions:
- The developed nanoplatform successfully navigates physiological barriers, overcoming key challenges in nanomedicine translation.
- This integrated approach offers a clinically promising strategy for effective and safer anticancer therapy.
More Related Videos
Related Concept Videos
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Modified-Release Drug Delivery Systems: Site-Targeted
Modified-Release Drug Delivery Systems: Rate-Programmed II
Oral Drug Delivery Systems: Continuous-Release Systems
Modified-Release Drug Delivery Systems: Rate-Programmed I
Modified-Release Drug Delivery Systems: Stimuli-Activated

